ScreenerHero

QUREuniQure N.V.

NAS · US · Healthcare · Biotechnology · uniqure.com
48.37USD-1.06%Mkt Cap: 3.36B $P/E: —

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases in the United States. The company offers HEMGENIX that allows people living with hemophilia B to produce factor IX, which c…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$138.82BUSDP/E 31.9
REGN
Regeneron Pharmaceuticals, Inc.
$85.87BUSDP/E 20.5
ARGX
ARGENX SE
$61.34BUSDP/E 39.8
ARGX
argenx SE
$65.05BUSDP/E 39.6
MRNA
Moderna, Inc.
$57.94BUSD
UCB
UCB SA
$45.95BUSDP/E 19.6
RVMD
Revolution Medicines, Inc.
$44.89BUSD
ONC
BeOne Medicines AG
$42.36BUSDP/E 67.2
RPRX
Royalty Pharma Plc Class A
$35.43BUSDP/E 32.6
ALNY
Alnylam Pharmaceuticals, Inc.
$31.61BUSDP/E 41.2
BNTX
BioNTech SE
$29.28BUSD
INSM
Insmed Incorporated
$27.47BUSD
ROIV
Roivant Sciences Ltd. Common Shares
$26.22BUSD
INCY
Incyte Corporation
$25.91BUSDP/E 16.2
GMAB
Genmab A/S
$20.86BUSDP/E 26.3
GMAB
Genmab A/S
$19.26BUSDP/E 26.6
ASND
Ascendis Pharma A/S
$16.61BUSDP/E 19.6
JAZZ
Jazz Pharmaceuticals plc
$16.51BUSDP/E 17.4
BBIO
BridgeBio Pharma, Inc.
$15.93BUSD
EXEL
Exelixis, Inc.
$13.40BUSDP/E 17.0

Key Statistics

Company
Market Cap3.36B $
Enterprise Value3.13B $
Revenue (TTM)18.67M $
Gross Profit14.41M $
Net Income (TTM)-198.97M $
Revenue/Share0.2990 USD
Last Price48.37 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees221
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-16.28
PEG—
EV/EBITDA-17.13
EV/Revenue167.80
P/S181.63
P/B10.46
EPS (TTM)-4.06
EPS (Forward)-3.00
52W Range
47.0946% of range49.85
52W High49.85 USD
52W Low47.09 USD
Profitability
Gross Margin89.53%
Oper. Margin-872.23%
EBITDA Margin0.00%
Profit Margin-1236.00%
ROE-100.04%
ROA-24.12%
Growth
Revenue Growth11.00%
Earnings Growth—
Cash Flow & Leverage
Operating CF-177.96M $
CapEx (TTM)439.00K $
FCF Margin-415.49%
FCF Yield-2.31%
Net Debt-258.17M $
Net Debt/EBITDA1.41
Balance Sheet
Debt/Equity0.32
Current Ratio10.01
Quick Ratio9.79
Book Value/Sh4.674 USD
Cash/Share11.68 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.3 (Strong Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)70.40 USD
Upside (mean)+45.5%
Target Range47.25 USD – 97.58 USD
$47.25+45.5% to mean$97.58
# Analysts11
Ownership
Shares Out.69.37M
Float57.52M
Insiders1.26%
Institutions96.19%
Short Interest
Short Ratio6.8d
Short % Float15.61%
Short % Out.15.40%
Shares Short10.68M
Short (prev mo.)11.49M
Technical
SMA 5041.84 (+15.6%)
SMA 20027.42 (+76.4%)
Beta0.94
S&P 52W Chg21.00%
Avg Vol (30d)934.60K
Avg Vol (10d)1.06M
Technical Indicators
RSI (14)64.5
MACD2.1776
MACD Signal1.9703
MACD Hist.+0.2073
BB Upper51.82 USD
BB Middle44.89 USD
BB Lower37.95 USD
BB Width30.90%
ATR (14)2.236 USD
Vol Ratio (20d)0.47x